BBIO Stock Forecast & Price Target

BridgeBio Pharma is experiencing a positive trajectory, as evidenced by an increase in full-year 2026 revenue forecasts, now projected at $766.3 million, alongside rising sales for its key program, Attruby (acoramidis), throughout its first year of launch. The company's advancements in clinical data for both BBP-418 and encaleret further bolster confidence, with the potential for regulatory approvals in the first half of 2026, indicating promising revenue generation across a de-risked portfolio. Additionally, robust activity in the prescribing of Attruby, with over 5,259 prescriptions written by 1,355 unique prescribers, highlights strong market traction and growth potential in the genetic disease treatment landscape.

BridgeBio Pharma faces a challenging financial outlook due to an anticipated net loss of $3.59 million for the full year 2025, coupled with a significant quarterly net loss of $182.7 million that exceeds consensus estimates. The company's high debt levels and limited cash reserves raise concerns about its ability to sustain operations or repay lenders in the event of clinical or commercial setbacks. Additionally, the potential introduction of generic alternatives to its key treatment, Attruby, and the risks associated with its pipeline programs, such as the Phase 3 trial for Infigratinib, further exacerbate the vulnerabilities in BridgeBio’s financial stability.